The Pharma Data

AUGUST 16, 2021

Better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies, and stronger memory B and T cell activation as compared to the first-generation candidate, CVnCoV.

Immune Response 52

Immune Response Vaccine Virus RNA 52

Broad Institute

JUNE 27, 2024

By Greta Friar, Whitehead Institute June 27, 2024 Images of a mouse brain show the effect of a technology called CHARM in turning off the expression of a gene in the brain. They used an engineered adeno-associated virus (AAV) that crosses the blood-brain barrier after intravenous administration. Credit: Neumann EN, Bertozzi TM, et al.

Disease 142

Disease Therapies Clinical Trials Engineering 142

Advarra

JANUARY 11, 2024

mRNA Cancer Vaccines mRNA cancer vaccines represent a newer class of vaccines utilizing mRNA’s ability to encode for almost any protein, while maintaining an acceptable safety profile with flexible delivery and production processes.

Vaccine 52

Vaccine Therapies Clinical Trials Small Molecule 52

Codon

APRIL 9, 2023

AI + Bio *Transfer learning for cross-context prediction of protein expression from 5’UTR sequence. Read Rational design of a highly immunogenic prefusion-stabilized F glycoprotein antigen for a respiratory syncytial virus vaccine. Biology is the world’s most advanced technology. Subscribe to learn more. McGrady N.R.

Therapies 52

Therapies RNA Engineering Vaccine 52

The Pharma Data

OCTOBER 26, 2020

In addition, the observed median PFS shows that the regimen can induce a sustained and durable response, which is also shown consistently by the induction of a specific immune response. This response developed as early as D43 and sustained at 6 months after initiation of therapy, consistent with the durable disease-control.

Vaccine 40

Vaccine Trials Treatment Virus 40